---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000528"
form_type: "8-K"
ticker: "GNLX"
cik: "0001231457"
company_name: "GENELUX Corp"
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:32:25.840645+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Genelux reports preliminary cash ~$30.9M; positive Olvi-Vec SCLC data and FDA guidance for PRROC

## Summary
- Preliminary cash, cash equivalents, and short-term investments as of Dec 31, 2024: ~$30.9M (unaudited).
- Phase 1b/2 SCLC data: 71% disease control rate among 7 evaluable patients; 2 partial responses; 79% tumor reduction in one.
- FDA Type D meeting for Olvi-Vec in PRROC: FDA indicated clinically meaningful PFS advantage without OS decrement could support traditional approval; pre-BLA meeting recommended.
- Anticipates reporting Phase 3 topline (OnPrime/GOG-3076) in H1 2026 and Phase 2 VIRO-25 interim in H2 2025.

## SEC filing metadata
- accession: 0001641172-25-000528
- form_type: 8-K
- ticker: GNLX
- cik: 0001231457
- company_name: GENELUX Corp
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1231457/000164117225000528/0001641172-25-000528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1231457/000164117225000528/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000528
- JSON: https://secwatch.observer/filing/0001641172-25-000528.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000528.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.